Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany

Multiple Sclerosis Journal - Experimental Translational and Clinical, Journal Year: 2022, Volume and Issue: 8(1)

Published: Jan. 1, 2022

Evidence suggests that early highly efficacious therapy in relapsing multiple sclerosis is superior to escalation strategies.

Language: Английский

---

Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal

PharmacoEconomics - Open, Journal Year: 2022, Volume and Issue: 7(2), P. 229 - 241

Published: Dec. 1, 2022

Ocrelizumab demonstrated significant clinical benefit for the treatment of relapsing (RMS) and primary progressive (PPMS) multiple sclerosis (MS), an incurable disease characterized by disability progression. This study evaluated economic impact ocrelizumab relative to current practice, including other disease-modifying therapies (DMT), available in Portugal.Markov models MS were adapted estimate across three patient populations: treatment-naïve RMS, previously treated PPMS. Health states defined according Expanded Disability Status Scale. For model further captured occurrence relapses progression secondary (SPMS). A lifetime time-horizon Portuguese societal perspective adopted.For RMS patients, was estimated maximize expected time (years) without SPMS (10.50) natalizumab (10.10), dimethyl fumarate (8.64), teriflunomide (8.39), fingolimod (8.38), interferon β-1a (8.33) glatiramer acetate (8.18). As most effective option, with quality-adjusted life year (QALY) gains between 0.3 1.2, found be cost-saving fingolimod, presented incremental cost-effectiveness ratios (ICER) below €16,720/QALY remaining DMT. PPMS ICER versus best supportive care at €78,858/QALY.Ocrelizumab provides important health benefits comparing favourably widely used therapies. In revealed either or have costs-per-QALY likely commonly accepted thresholds. PPMS, fills a clear gap practice. Overall, is provide good value money addressing need patients.

Language: Английский

---

Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis

Multiple Sclerosis and Related Disorders, Journal Year: 2020, Volume and Issue: 43, P. 102211 - 102211

Published: May 24, 2020

Language: Английский

---

Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis

Neurological Sciences, Journal Year: 2024, Volume and Issue: 45(7), P. 3379 - 3387

Published: Jan. 26, 2024

Abstract Background Autologous haematopoietic stem cell transplantation (AHSCT) is a highly effective one-off treatment for relapsing–remitting multiple sclerosis (RR-MS), potentially representing an optimal front-loading strategy costs. Objective Exploring cost/effectiveness of AHSCT and high-efficacy disease-modifying treatments (HE-DMTs) in RR-MS, estimating costs at our centre Italy, where National Health Service (NHS) provides universal health coverage. Methods Costs (including drugs, inpatient/outpatient management) with HE-DMTs were calculated as NHS expenditures over 2- 5-year periods. Cost-effectiveness each was estimated “cost needed to treat” (CNT), i.e. expense prevent relapses, progression, or disease activity (NEDA) one patient n -years, retrieving outcomes from published studies. Results similar 2 years, whereas cheaper than most 5 years (€46 600 vs €93 800, respectively). When cost-effectiveness treatments, mean CNT NEDA twofold that AHSCT, it relapses disability. Differences remarkable especially NEDA, being €382 800 €74 900 AHSCT. Conclusions may be cost-effective selected aggressive RR-MS. Besides priceless benefits treated individuals, cost-savings generated by contribute improving healthcare assistance population level.

Language: Английский

---

Exploring the impact of exercise and essential amino acid plus cholecalciferol supplementation on physical fitness and body composition in multiple sclerosis: A case study

Clinical Case Reports, Journal Year: 2023, Volume and Issue: 11(6)

Published: June 1, 2023

In MS patients, especially those frail or malnourished, combining home-based exercise twice weekly with essential amino acids and vitamin D may improve body composition, strength, physical performance, enabling long-term functional improvements.

Language: Английский

---